NAD+ metabolism and NAD+-dependent enzymes: Promising therapeutic targets for neurological diseases

Current Drug Targets

Volumn 13, Issue 2, 2012, Pages 222-229

  Ma, Yingxin ^b   Chen, Heyu ^b   He, Xin ^b   Nie, Hui ^b   Hong, Yunyi ^b   Sheng, Caibin ^b   Wang, Qing ^c   Xia, Weiliang ^b   Ying, Weihai ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Calcium homeostasis; Cell death; NAD+; Neurological diseases; Oxidative stress

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; SIRTUIN;

ALZHEIMER DISEASE; ARTICLE; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN TUMOR; CELL DEATH; CELL SURVIVAL; CYTOTOXICITY; ENZYME INHIBITION; MITOCHONDRIAL PERMEABILITY; NERVE FIBER DEGENERATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS;

ANIMALS; HUMANS; MOLECULAR TARGETED THERAPY; NAD; NERVOUS SYSTEM DISEASES; NEUROPROTECTIVE AGENTS; POLY(ADP-RIBOSE) POLYMERASES; SIRTUINS;

EID: 84863116397     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012799201711     Document Type: Article

References (89)

1. Ying W. Deleterious network hypothesis of Alzheimer's disease. Med Hypotheses 1996; 46: 421-428.
2. Ying W. A new hypothesis of neurodegenerative diseases: the deleterious network hypothesis. Med Hypotheses 1996; 47: 307-313.
3. Ying W. Deleterious network: a testable pathogenetic concept of Alzheimer's disease. Gerontology 1997; 43: 242-253.
4. Chan PH. Role of oxidants in ischemic brain damage. Stroke 1996; 27: 1124-1149.
5. Chan PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 2001; 21: 2-14.
6. Starkov AA, Chinopoulos C, Fiskum G. Mitochondrial calcium and oxidative stress as mediators of ischemic brain injury. Cell Calcium 2004; 36: 257-264.
7. del Zoppo GJ. Inflammation and the neurovascular unit in the setting of focal cerebral ischemia. Neuroscience 2009; 158: 972-982.
8. Xia W, Han J, Huang G, Ying W. Inflammation in Ischemic Brain Injury: Current Advances and Future Perspectives. Clin Exp Pharmacol Physiol 2010; 37: 253-258.
9. Berger NA. Poly(ADP-ribose) in the cellular response to DNA damage. Radiat Res 1985; 101: 4-15.
10. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002; 54: 375-429.
11. Chen J, Zhou Y, Mueller-Steiner S, et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NFkappaB signaling. J Biol Chem 2005; 280: 40364-40374.
12. Outeiro TF KE, Altmann SM, Kufareva I, et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007; 317: 516-519.
13. + profoundly decreases brain injury in a rat model of transient focal ischemia. Front Biosci 2007; 12: 2728-2734.
14. Maiese K, Chong ZZ. Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain. Trends Pharmacol Sci 2003; 24: 228-232.
15. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADPribosyl) ation reactions in the regulation of nuclear functions. Biochem J 1999; 342 (Pt 2): 249-268.
16. +/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid Redox Signal 2008; 10: 179-206.
17. + repletion prevents PARP- 1-induced glycolytic blockade and cell death in cultured mouse astrocytes. Biochem Biophys Res Commun 2003; 308: 809-813.
18. + depletion and mitochondrial permeability transition. J Biol Chem 2004; 279:18895-18902.
19. + depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death. J Neurosci; 30: 2967-2978.
20. Alano CC, Beutner G, Dirksen RT, Gross RA, Sheu SS. Mitochondrial permeability transition and calcium dynamics in striatal neurons upon intense NMDA receptor activation. J Neurochem 2002; 80: 531-538.
21. + can restore intracellular ATP levels and prevent PC12 cell death induced by oxidative stress. FASEB Journal 2010: lb471 (American Society for Neurosciences Annual Meeting Abstracts).
22. Ziegler M. New functions of a long-known molecule. Emerging roles of NAD in cellular signaling. Eur J Biochem 2000; 267: 1550-1564.
23. Kim EJ, Kho JH, Kang MR, Um SJ. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol Cell 2007; 28: 277-290.
24. Salminen A, Kauppinen A, Suuronen T, Kaarniranta K. SIRT1 longevity factor suppresses NF-kappaB -driven immune responses: regulation of aging via NF-kappaB acetylation? Bioessays 2008; 30: 939-942.
25. Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease--a double-edged sword. Neuron 2002; 35: 419-432.
26. Gao HM, Hong JS. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 2008; 29: 357-365.
27. Hassa PO, Hottiger MO. A role of poly (ADP-ribose) polymerase in NF-kappaB transcriptional activation. Biol Chem 1999; 380: 953-959.
28. Kameoka M, Ota K, Tetsuka T, et al. Evidence for regulation of NF-kappaB by poly(ADP-ribose) polymerase. Biochem J 2000; 346 Pt 3: 641-649.
29. Ditsworth D, Zong WX, Thompson CB. Activation of poly(ADP)- ribose polymerase (PARP-1) induces release of the proinflammatory mediator HMGB1 from the nucleus. J Biol Chem 2007; 282: 17845-17854.
30. Luo HR, Hattori H, Hossain MA, et al. Akt as a mediator of cell death. Proc Natl Acad Sci U S A 2003; 100: 11712-11717.
31. Kovacs K, Toth A, Deres P, et al. Critical role of PI3-kinase/Akt activation in the PARP inhibitor induced heart function recovery during ischemia-reperfusion. Biochem Pharmacol 2006; 71: 441-452.
32. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-241.
33. Brunet A, Datta SR, Greenberg ME. Transcription-dependent and - independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol 2001; 11: 297-305.
34. Fonfria E, Marshall IC, Benham CD, et al. TRPM2 channel opening in response to oxidative stress is dependent on activation of poly(ADP-ribose) polymerase. Br J Pharmacol 2004; 143: 186-192.
35. Yang KT, Chang WL, Yang PC, et al. Activation of the transient receptor potential M2 channel and poly(ADP-ribose) polymerase is involved in oxidative stress-induced cardiomyocyte death. Cell Death Differ 2005; 13: 1815-1826.
36. Fonfria E, Marshall IC, Boyfield I, et al. Amyloid beta-peptide(1- 42) and hydrogen peroxide-induced toxicity are mediated by TRPM2 in rat primary striatal cultures. J Neurochem 2005; 95: 715-723.
37. Guarente L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev 2000; 14: 1021-1026.
38. Dali-Youcef N, Lagouge M, Froelich S, Koehl C, Schoonjans K, Auwerx J. Sirtuins: the 'magnificent seven', function, metabolism and longevity. Ann Med 2007; 39: 335-345.
39. Kolthur-Seetharam U, Dantzer F, McBurney MW, de Murcia G, Sassone-Corsi P. Control of AIF-mediated cell death by the functional interplay of SIRT1 and PARP-1 in response to DNA damage. Cell Cycle 2006; 5: 873-877.
40. Cai AL, Zipfel GJ, Sheline CT. Zinc neurotoxicity is dependent on intracellular NAD levels and the sirtuin pathway. Eur J Neurosci 2006; 24: 2169-2176.
41. Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-kappaBdependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004; 23: 2369-2380.
42. Wang F, Nguyen M, Qin FX, Tong Q. SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell 2007; 6: 505-514.
43. Nie H, Chen H, Han J, et al. Silencing of SIRT2 induces cell death and a decrease in the intracellular ATP level of PC12 cells. Int J Physiol Pathophysiol Pharmacol 2011; 3: 65-70.
44. + levels dictate cell survival. Cell 2007; 130: 1095-1107.
45. + depletion and mitochondrial permeability transition. J Biol Chem 2004; 279: 18895-18902.
46. Wang S, Xing Z, Vosler PS, et al. Cellular NAD replenishment confers marked neuroprotection against ischemic cell death: role of enhanced DNA repair. Stroke 2008; 39: 2587-2595.
47. + depletion and reduced Sir2alpha deacetylase activity. J Biol Chem 2005; 280: 43121-43130.
48. + blocks H2O2- induced HMGB1 translocation of PC12 cells and decreases survival of microglia. FASEB Journal 2010: lb469 (American Society for Neurosciences Annual Meeting Abstracts).
49. Eliasson MJ, Sampei K, Mandir AS, et al. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat Med 1997; 3: 1089-1095.
50. Endres M, Wang ZQ, Namura S, Waeber C, Moskowitz MA. Ischemic brain injury is mediated by the activation of poly(ADPribose) polymerase. J Cereb Blood Flow Metab 1997; 17: 1143-1151.
51. Goto S, Xue R, Sugo N, et al. Poly(ADP-ribose) polymerase impairs early and long-term experimental stroke recovery. Stroke 2002; 33: 1101-1106.
52. Love S, Barber R, Wilcock GK. Neuronal accumulation of poly(ADP-ribose) after brain ischaemia. Neuropathol Appl Neurobiol 1999; 25: 98-103.
53. Hurn PD, Vannucci SJ, Hagberg H. Adult or perinatal brain injury: does sex matter? Stroke 2005; 36: 193-195.
54. McCullough LD, Zeng Z, Blizzard KK, Debchoudhury I, Hurn PD. Ischemic nitric oxide and poly (ADP-ribose) polymerase-1 in cerebral ischemia: male toxicity, female protection. J Cereb Blood Flow Metab 2005; 25: 502-512.
55. Hagberg H, Wilson MA, Matsushita H, et al. PARP-1 gene disruption in mice preferentially protects males from perinatal brain injury. J Neurochem 2004; 90: 1068-1075.
56. Nagayama T, Simon RP, Chen D, et al. Activation of poly(ADPribose) polymerase in the rat hippocampus may contribute to cellular recovery following sublethal transient global ischemia. J Neurochem 2000; 74: 1636-1645.
57. Yang Y, Candelario-Jalil E, Thompson JF, et al. Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia. J Neurochem; 112: 134-149.
58. + synthesis in cardiac myocytes. Circ Res 2009; 105: 481-491.
59. Della-Morte D, Dave KR, DeFazio RA, Bao YC, Raval AP, Perez-Pinzon MA. Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1-uncoupling protein 2 pathway. Neuroscience 2009; 159: 993-1002.
60. Kakefuda K, Fujita Y, Oyagi A, et al. Sirtuin 1 overexpression mice show a reference memory deficit, but not neuroprotection. Biochem Biophys Res Commun 2009; 387: 784-788.
61. Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol; 5: 253-295.
62. Imai SI, Guarente L. Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases. Trends Pharmacol Sci. 2010; 31:212-220.
63. Guarente L. Sirtuins in aging and disease. Cold Spring Harb Symp Quant Biol 2007; 72: 483-488.
64. + treatment decreases tumor cell survival by inducing oxidative stress. Front Biosci (Elite Ed); 3: 434-441.
65. Han J, Shi S, Min L, Wu T, Xia W, Ying W. NAD(+) Treatment Induces Delayed Autophagy in Neuro2a Cells Partially by Increasing Oxidative Stress. Neurochem Res 2011; 36: 2270-2277.
66. Ma Y CH, Xia W, Ying W. Oxidative stress and PARP activation mediate the NADH-induced decrease in glioma cell survival. Int J Physiol Pathophysiol Pharmacol 2011; 3: 21-28.
67. Tentori L, Leonetti C, Scarsella M, et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 2003; 9: 5370-5379.
68. Tentori L, Portarena I, Torino F, Scerrati M, Navarra P, Graziani G. Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells. Glia 2002; 40: 44-54.
69. Voelter-Mahlknecht S, Ho AD, Mahlknecht U. FISH-mapping and genomic organization of the NAD-dependent histone deacetylase gene, Sirtuin 2 (Sirt2). Int J Oncol 2005; 27: 1187-1196.
70. Hiratsuka M, Inoue T, Toda T, et al. Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun 2003; 309: 558-566.
71. Ying W. Deleterious network hypothesis of aging. Med Hypotheses 1997; 48: 143-148.
72. Wolozin B, Golts N. Iron and Parkinson's disease. Neuroscientist 2002; 8: 22-32.
73. Beal MF. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J Bioenerg Biomembr 2004; 36: 381-386.
74. Cosi C, Colpaert F, Koek W, Degryse A, Marien M. Poly(ADPribose) polymerase inhibitors protect against MPTP-induced depletions of striatal dopamine and cortical noradrenaline in C57B1/6 mice. Brain Res 1996; 729: 264-269.
75. Mandir AS, Simbulan-Rosenthal CM, Poitras MF, et al. A novel in vivo post-translational modification of p53 by PARP-1 in MPTPinduced parkinsonism. J Neurochem 2002; 83: 186-192.
76. Mandir AS, Przedborski S, Jackson-Lewis V, et al. Poly(ADPribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6- tetrahydropyridine (MPTP)-induced parkinsonism. Proc Natl Acad Sci U S A 1999; 96: 5774-5779.
77. Iwashita A, Yamazaki S, Mihara K, et al. Neuroprotective effects of a novel poly(ADP-ribose) polymerase-1 inhibitor, 2-[3-[4-(4- chlorophenyl)-1-piperazinyl] propyl]-4(3H)-quinazolinone (FR255595), in an in vitro model of cell death and in mouse 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Pharmacol Exp Ther 2004; 309: 1067-1078.
78. Przedborski S, Jackson-Lewis V, Djaldetti R, et al. The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci 2000; 16: 135-142.
79. Garske AL, Smith BC, Denu JM. Linking SIRT2 to Parkinson's disease. ACS Chem Biol 2007; 2: 529-532.
80. Yang J, He L, Wang J, Adams JD, Jr. Early administration of nicotinamide prevents learning and memory impairment in mice induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Pharmacol Biochem Behav 2004; 78: 179-183.
81. Birkmayer JG, Vrecko C, Volc D, Birkmayer W. Nicotinamide adenine dinucleotide (NADH)--a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application. Acta Neurol Scand Suppl 1993; 146: 32-35.
82. Kuhn W, Muller T, Winkel R, et al. Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis. J Neural Transm 1996; 103: 1187-1193.
83. Swerdlow RH. Is NADH effective in the treatment of Parkinson's disease? Drugs Aging 1998; 13: 263-28.
84. Qin W, Yang T, Ho L, et al. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer's disease amyloid neuropathology by calorie restriction. J Biol Chem 2006; 281: 21745-21754.
85. Anekonda TS, Reddy PH. Neuronal protection by sirtuins in Alzheimer's disease. J Neurochem 2006; 96: 305-313.
86. Guillemin GJ, Williams KR, Smith DG, Smythe GA, Croitoru-Lamoury J, Brew BJ. Quinolinic acid in the pathogenesis of Alzheimer's disease. Adv Exp Med Biol 2003; 527: 167-176.
87. Coleman M. Axon degeneration mechanisms: commonality amid diversity. Nat Rev Neurosci 2005; 6: 889-898.
88. Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 2004; 305: 1010-1013.
89. Wang J, Zhai Q, Chen Y, et al. A local mechanism mediates NADdependent protection of axon degeneration. J Cell Biol 2005; 170: 349-355.